Synthesis, antimicrobial activity, pharmacophore modeling and molecular docking studies of new pyrazole-dimedone hybrid architectures

Table 1 Results of cup-plate method expressed as minimum inhibitory concentrations (MIC) of the compounds in (μg/L)

Entry	Compounds	Gram positive bacteria						Yeast
		S. aureus ATCC 29213		E. faecalis ATCC29212		B. subtilis ATCC10400		C. albicans ATCC 2091
		CPM (mm)	MIC (µg/L)	CPM (mm)	MIC (µg/L)	CPM (mm)	MIC (µg/L)	CPM (mm)	MIC (µg/L)
1	4a	13	32	14	32	12	32	14	32
2	4b	15	32	13	16	15	16	15	32
3	4c	13	32	24	32	16	32	15	16
4	4d	16	32	16	32	18	32	16	16
5	4e	19	16	15	32	14	64	14	32
6	4f	14	32	13	64	15	32	14	32
7	4g	14	32	15	32	16	32	14	32
8	4h	12	64	14	32	16	32	17	16
9	4i	14	32	12	64	17	32	14	32
10	4j	10	64	13	32	10	32	13	32
11	4k	13	32	13	32	20	8	15	16
12	4l	16	16	16	32	16	32	14	32
13	4m	15	32	13	32	12	32	16	16
14	4n	14	32	13	32	15	32	14	32
15	4o	13	32	20	32	15	16	21	4
STD	Ciprofloxacin	27	≤ 0. 25	24	≤ 0.25	25	≤ 0.25	ND	ND
STD	Fluconazole	ND	ND	ND	ND	ND	ND	28	0.5

ISSN: 2661-801X